{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Solid Biosciences Inc."},"Symbol":{"label":"Symbol","value":"SLDB"},"Address":{"label":"Address","value":"500 RUTHERFORD AVENUE,THIRD FLOOR THIRD FLOOR, CHARLESTOWN, Massachusetts, 02129, United States"},"Phone":{"label":"Phone","value":"+1 617 337-4680"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit https://www.solidbio.com."},"CompanyUrl":{"label":"Company Url","value":"https://www.solidbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alexander Gery Cumbo","title":"President, Chief Executive Officer & Director"},{"name":"David Tyronne Howton","title":"Chief Operating Officer"},{"name":"Gabriel Brooks","title":"Chief Medical Officer"},{"name":"Paul Herzich","title":"Chief Technology Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}